Cytomegalovirus infection after solid-organ transplantation its risk factors direct and indirect effects and prevention strategies;A cytomegalovírus-fertozés rizikófaktorai, hatásai és a megelozés lehetoségei trnazplantáciot kovetoen

Orvosi Hetilap

Volumn 149, Issue 12, 2008, Pages 551-558

  Varga, Marina ^a,c   Remport, Ádám ^a   Czebe, Krisztina ^b   Péter, Antal ^a   Toronyi, Éva ^a   Sárváry, Eniko ^a   Fehérvári, Imre ^a   Sulyok, Beáta ^a   Járay, Jeno ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^c NONE   (Hungary)

Author keywords

Cytomegalovirus; Pre emptive therapy; Prophylaxis; Risk factor; Solid organ transplantation

Indexed keywords

BENZIMIDAVIR; CYTOKINE; GANCICLOVIR; LYMPHOCYTE ANTIBODY; OKT 3; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EVIDENCE BASED PRACTICE; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT CODING; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

EID: 42049097322     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28324     Document Type: Review

References (45)

1. Paya, C. V., Razonable, P. R.: Cytomegalovirus infection after organ transplantation. Transplant Infections. Szerk.: Bowden R. A., Ljungman P., Paya C. V., Lippencott, Williams and Wikins. 2003, 298-325.
2. Varga M., Görög D., Kári D. és mtsai: Szervdonorok virológiai szurése és a hazai lakosság átfertozöttsége humán cytomegalovírussal. Orv. Hetil., 2001, 142, 2631-2633.
3. Patel, R., Paya, C. V.: Infections in solid-organ transplant recipients. Clin. Microbiol. Rev., 1997, 10, 86-124.
4. Sagedal, S., Rollag, H., Hartmann, A.: Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin. Transplant., 2007, 21, 309-313.
5. Ljungman, P., Griffith, P., Paya, C.: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis., 2002, 34, 1094-1097.
6. Castens, J., Andersen, H. K., Spencer, E. és mtsa: Cytomegalovirus infection in renal transplant recipients. Transpl. Infect. Dis., 2006, 8, 203-212.
7. Humar, A., Mazzulli, T., Moussa, G. és mtsai:. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am. J. Transplant., 2005, 5, 1065-1070.
8. Preiksaitis, J. K., Brennan, D. C., Fishman, J. és mtsa: Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am. J. Transplant., 2005, 5, 218-227.
9. Blackwell, M.: Cytomegalovirus. Am. J. Transplant., 2004, 4, 51-58.
10. Reischig, T., Jindra, P., Mares, J. és mtsai: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation, 2005, 79, 317-324.
11. Freeman, R. B., Paya, C., Pescovitz, M. D. és mtsai: Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation, 2004, 78, 1765-1773.
12. Fan, J., Meng, X. Q., Yang, M. F és mtsai: Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation. Hepatobiliary Pancreat. Dis. Int., 2006, 5, 34-38.
13. Chen, Y., Rocha, V., Bittencourt, H. és mtsai: Relationship between HLA alleles and cytomegalovirus infection after allogenic hematopoietic stem cell transplant. Blood, 2001, 96, 500-501.
14. Fishman, J. A., Rubin, R. H.: Infection in organ-transplant recipients. N. Engl. J. Med., 1998, 338, 1741-1751.
15. Emery, V.: Facing the facts: the indirect effects of cytomegalovirus. Transplantation, 2007, 84, 7-10.
16. Sagedal, S., Hartmann, A., Nordal, K. P. és mtsai: Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int., 2004, 66, 329-337.
17. Ricart, M. J., Malaise, J., Moreno, A. és mtsai: Cytomegalovirus: occurrence, severity and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol. Dial. Transplant., 2005, 20, 1125-1132.
18. Grattan, M. T., Moreno-Cabral, C. E., Starnes, V. A. és mtsai: Cytomegalovirus infection is associated with cardiac allograft rejection and athrosclerosis. JAMA, 1989, 261, 3561-3566.
19. Martelius, T., Krogerus, L., Hockerstedt, K. és mtsai: Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology, 1998, 27, 996-1002.
20. Betjes, M. G. H., Litjens, N. H. R., Zietse, R.: Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol. Dial. Transplant., 2007, 22, 3298-3303.
21. Speir, E., Modali, R., Huang, E. S. és mtsa: Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science, 1994, 265, 391-394.
22. Gredmark, S., Strååt, K., Homman-Loudiyi, M. és mtsai: Human cytomegalovirus downregulates expression of receptors for platelet-derived growth factor by smooth muscle cells. J Virol., 2007, 81, 5112-5120.
23. Valantine, H. A.: The role of viruses in cardiac allograft vasculopathy. Am. J. Transplant., 2004, 4, 169-177.
24. Speir, E.: Cytomegalovirus gene regulation by reactive oxygen species: agents in atherosclerosis. Ann. NY Acad. Sci., 2000, 899, 363-374.
25. Söderberg-Nauclér, C.: Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med., 2006, 259, 219-246.
26. Boeckh, M., Nichols, W. G.: Immunsuppressive effects of beta-herpesviruses. Herpes, 2003, 10, 12-16.
27. Hjelmesaeth, J., Sagedal, S., Hartmann, A. és mtsa: Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired release after renal transplantation. Diabetologia, 2004, 47, 1550-1556.
28. Schnitzler, M. A.: Costs and consequences of cytomegalovirus disease. Am. J. Health. Syst. Pharm., 2003, 60, 5-8.
29. Schnitzler, M. A., Lowell, J. A., Hardinger, K. L. és mtsai: The association of cytomegalovirus sero-pairung with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am. J. Transplant., 2003, 3, 445-451.
30. Paston, S. J., Dodi, I. A., Madrigal J. A.: Progress made towards the development of a CMV peptide vaccine. Human Immunology, 2004, 65, 544-549.
31. Gönczöl, É., Plotkin, S.: Development of a cytomegalovirus vaccine: Lessons from recent clinical trials. Expert. Opin. Biol. Ther., 2001, 1, 401-412.
32. Lu, H. és Thomas, S.: Maribavir. Curr. Opin. Investig. Drugs, 2004, 5, 898-906.
33. Sudarsanam, T. D., Sahni, R. D., John, G. T.: Leflunomide: a possible alternative for ganciclovir sensitive and resistant cytomegalovirus infections. Postgrad. Med. J., 2006, 82, 313-314.
34. Baillie, G. M.: Prevention of cytomegalovirus disease in solid organ transplant patients: Prophylactic versus preemptive therapy. Am. J. Health-Syst. Pharm., 2006, 63, 10-18.
35. Slifkin, M., Doron, S., Snydman, D. R.: Viral prophylaxis in organ transplant patients. Drugs, 2004, 64, 2763-2792.
36. Boivin, G., Goyette, N., Gilbert, C. és mtasai: Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis., 2004, 189, 1615-1618.
37. Pescovitz, M. D.: A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus. Kidney Int., 2007, 72, 912-913.
38. Levitsky, J., Singh, N., Wagener, M. M. és mtsai: A Survey of CMV Prevention Strategies after liver transplantation. Am. J. Transplant., 2008, 8, 158-161.
39. Kruger, R. M., Paranjothi, S., Storch, G. A. és mtsai: Impact of prophylaxis with cytogam alone on the incidence of CMV viraemia in CMV-seropositive lung transplant recipients. J. Heart Lung Transplant., 2003, 22, 754-763.
40. Humar A.: Cytomegalovirus prevention: prophylaxis and preemptive therapy. Transplantation, 2007, 84, 11-14.
41. Pescovitz, M. D.: Antiviral therapies for cytomegalovirus in solid-organ transplantation. Transplantation, 2007, 84 (Suppl.), 2-6.
42. Bueno, J., Ramil, C., Green, M.: Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Pediatr. Drugs, 2002, 4, 279-290.
43. Varga M., Remport Á., Hídvégi M. és mtsai: Comparing cytomegalovirus prophylaxis in renal transplantation: single centre experience. Transpl. Infect. Dis., 2005, 7, 63-67.
44. Kliem, V., Fricke, L., Wollbrink, T. és mtsai: Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant., 2008, 8, 1-9.
45. Czebe K., Antus B., Varga M. és mtsa: Tüdotranszplantált betegek pumonális infekciói. Orv. Hetil., 2008, 149, 99-109.